Condition

Recurrent Primary Peritoneal Carcinoma

ClinicalTrials.gov condition label

Clinical trials12

Recruiting2

Common interventions25

Lead sponsors shown6

Clinical trials

12 shown

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTFNCT03604315 · 2018-12-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520 · 2021-03-31

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric PatientsNCT04213794 · 2019-11-08

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerNCT02996825 · 2017-10-02

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerNCT02627430 · 2016-03-01

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianNCT02208375 · 2014-11-11

ACTIVE_NOT_RECRUITING

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerNCT01606241 · 2012-07-24

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerNCT01145430 · 2010-06-01

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerNCT01010126 · 2009-09-08

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyNCT00892736 · 2009-04-20

Collecting Tumor Samples From Patients With Gynecological TumorsNCT00897442 · 1992-06-01

Common interventions

Leading sponsors

National Cancer Institute (NCI)5 M.D. Anderson Cancer Center2 Mayo Clinic2 City of Hope Medical Center1 Gynecologic Oncology Group1 Pamela Munster1

Trial status mix

COMPLETED6

RECRUITING2

WITHDRAWN2

ACTIVE_NOT_RECRUITING1

TERMINATED1

Phase mix

PHASE18

PHASE22

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.